BACKGROUND: The beta(2)-adrenergic receptor (ADRB2) is the most common adrenergic receptor in the lung, and associations between ADRB2 polymorphisms and intermediate phenotypes of asthma have been reported. Four missense polymorphisms (Arg16Gly, Gln27Glu, Val34Met, and Thr164Ile) and one polymorphism in the 5' leader cistron of the ADRB2 messenger RNA has been identified. In vitro studies have shown that these missense polymorphisms can affect ADRB2 function. METHODS: To examine possible associations of ADRB2 polymorphisms with asthma susceptibility, we performed transmission disequilibrium tests (TDT) of 137 Japanese families identified through children with atopic asthma. RESULTS: We did not find associations between any alleles of the ADRB2 polymorphisms and asthma by TDT (p > 0.1). We also performed a meta-analysis of data from all available studies. The random-effects model showed no significant odds ratio for the Arg16Gln (odds ratio = 1.05, p = 0.53) or Gln27Glu (odds ratio = 1.12, p = 0.22) polymorphism. CONCLUSION: Our data indicate that ADRB2 does not contribute substantially to susceptibility to asthma, but it is possible that these polymorphisms influence disease activity and drug responses in individuals with asthma. Copyright 2004 S. Karger AG, Basel
BACKGROUND: The beta(2)-adrenergic receptor (ADRB2) is the most common adrenergic receptor in the lung, and associations between ADRB2 polymorphisms and intermediate phenotypes of asthma have been reported. Four missense polymorphisms (Arg16Gly, Gln27Glu, Val34Met, and Thr164Ile) and one polymorphism in the 5' leader cistron of the ADRB2 messenger RNA has been identified. In vitro studies have shown that these missense polymorphisms can affect ADRB2 function. METHODS: To examine possible associations of ADRB2 polymorphisms with asthma susceptibility, we performed transmission disequilibrium tests (TDT) of 137 Japanese families identified through children with atopic asthma. RESULTS: We did not find associations between any alleles of the ADRB2 polymorphisms and asthma by TDT (p > 0.1). We also performed a meta-analysis of data from all available studies. The random-effects model showed no significant odds ratio for the Arg16Gln (odds ratio = 1.05, p = 0.53) or Gln27Glu (odds ratio = 1.12, p = 0.22) polymorphism. CONCLUSION: Our data indicate that ADRB2 does not contribute substantially to susceptibility to asthma, but it is possible that these polymorphisms influence disease activity and drug responses in individuals with asthma. Copyright 2004 S. Karger AG, Basel
Authors: J Michael Collaco; SeEun Jennifer Choi; Kristin A Riekert; Michelle N Eakin; Sharon A McGrath-Morrow; Sande O Okelo Journal: Pediatr Pulmonol Date: 2011-02-15
Authors: Xiaobo Li; Yonggang Zhang; Jie Zhang; Yuling Xiao; Jin Huang; Can Tian; Chao He; Yao Deng; Yingying Yang; Hong Fan Journal: Respir Res Date: 2010-09-24
Authors: Augusto A Litonjua; Li Gong; Qing Ling Duan; Jaekyu Shin; Mariellen J Moore; Scott T Weiss; Julie A Johnson; Teri E Klein; Russ B Altman Journal: Pharmacogenet Genomics Date: 2010-01 Impact factor: 2.089
Authors: Chengwei Wang; Muhammad T Salam; Talat Islam; Madé Wenten; W James Gauderman; Frank D Gilliland Journal: Pediatrics Date: 2008-06-16 Impact factor: 7.124
Authors: Ana Carolina Zimiani de Paiva; Fernando Augusto de Lima Marson; José Dirceu Ribeiro; Carmen Sílvia Bertuzzo Journal: Allergy Asthma Clin Immunol Date: 2014-02-05 Impact factor: 3.406